Hepatitis B Virus Reactivation After Three-Dimensional Conformal Radiotherapy in Patients With Hepatitis B Virus-Related Hepatocellular Carcinoma

International Journal of Radiation Oncology Biology Physics

Volumn 69, Issue 3, 2007, Pages 813-819

  Kim, Ji Hoon ^a   Park, Joong Won ^a   Kim, Tae Hyun ^a   Koh, Dong Wook ^a   Lee, Woo Jin ^a   Kim, Chang Min ^a  

^a National Cancer Center   (South Korea)

Author keywords

Chronic hepatitis B; Exacerbation; Hepatitis B virus; Hepatocellular carcinoma; Radiation induced liver disease; Reactivation

Indexed keywords

DISEASES; DNA; ONCOLOGY; RADIOTHERAPY;

ANTIVIRAL THERAPY; CHRONIC HEPATITIS B; CUMULATIVE RATES; EXACERBATION; HEPATITIS B VIRUS; HEPATOCELLULAR CARCINOMA;

VIRUSES;

LAMIVUDINE; VIRUS DNA;

3 DIMENSIONAL CONFORMAL RADIOTHERAPY; ADULT; ANTIVIRAL THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER DISEASE; MALE; PRIORITY JOURNAL; VIRUS ACTIVATION;

CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; RADIOTHERAPY, CONFORMAL; VIRUS ACTIVATION;

EID: 34548694742     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.04.005     Document Type: Article

References (33)

1. Bosch F.X., Ribes J., Diaz M., et al. Primary liver cancer: Worldwide incidence and trends. Gastroenterology 127 (2004) S5-S16
2. Parkin D.M., Bray F., Ferlay J., et al. Estimating the world cancer burden: Globocan 2000. Int J Cancer 94 (2001) 153-156
3. Bruix J., Sherman M., Llovet J.M., et al., for the European Association for the Study of the Liver. Clinical management of hepatocellular carcinoma: Conclusions of the Barcelona-2000 EASL conference. J Hepatol 35 (2001) 421-430
4. Bruix J., Sherman M., for the Practice Guidelines Committee, and American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 42 (2005) 1208-1236
5. Llovet J.M., Real M.I., Montana X., et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial. Lancet 359 (2002) 1734-1739
6. Yuen M.F., Chan A.O., Wong B.C., et al. Transarterial chemoembolization for inoperable, early stage hepatocellular carcinoma in patients with Child-Pugh grade A and B: Results of a comparative study in 96 Chinese patients. Am J Gastroenterol 98 (2003) 1181-1185
7. Stillwagon G.B., Order S.E., Guse C., et al. 194 Hepatocellular cancers treated by radiation and chemotherapy combinations: Toxicity and response: A Radiation Therapy Oncology Group study. Int J Radiat Oncol Biol Phys 17 (1989) 1223-1229
8. Emami B., Lyman J., Brown A., et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21 (1991) 109-122
9. Dawson L.A., McGinn C.J., Normolle D., et al. Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol 18 (2000) 2210-2218
10. Aoki K., Okazaki N., Okada S., et al. Radiotherapy for hepatocellular carcinoma: Clinicopathological study of seven autopsy cases. Hepatogastroenterology 41 (1994) 427-431
11. Yasuda S., Ito H., Yoshikawa M., et al. Radiotherapy for large hepatocellular carcinoma combined with transcatheter arterial embolization and percutaneous ethanol injection therapy. Int J Oncol 15 (1999) 467-473
12. Lawrence T.S., Robertson J.M., Anscher M.S., et al. Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys 31 (1995) 1237-1248
13. Dawson L.A., and Ten Haken R.K. Partial volume tolerance of the liver to radiation. Semin Radiat Oncol 15 (2005) 279-283
14. Cheng J.C., Wu J.K., Lee P.C., et al. Biologic susceptibility of hepatocellular carcinoma patients treated with radiotherapy to radiation-induced liver disease. Int J Radiat Oncol Biol Phys 60 (2004) 1502-1509
15. Cheng J.C., Wu J.K., Huang C.M., et al. Radiation-induced liver disease after three-dimensional conformal radiotherapy for patients with hepatocellular carcinoma: Dosimetric analysis and implication. Int J Radiat Oncol Biol Phys 54 (2002) 156-162
16. Cheng J.C., Wu J.K., Huang C.M., et al. Radiation-induced liver disease after radiotherapy for hepatocellular carcinoma: Clinical manifestation and dosimetric description. Radiother Oncol 63 (2002) 41-45
17. Park J.W., and for the Korean Liver Cancer Study Group and National Cancer Center. [Practice guideline for diagnosis and treatment of hepatocellular carcinoma.]. Korean J Hepatol 10 (2004) 88-98
18. Ueno S., Tanabe G., Nuruki K., et al. Prognostic performance of the new classification of primary liver cancer of Japan (4th edition) for patients with hepatocellular carcinoma: A validation analysis. Hepatol Res 24 (2002) 395-403
19. Lok A.S., McMahon B.J., for the Practice Guidelines Committee, and American Association for the Study of Liver Diseases (AASLD). Chronic hepatitis B. Hepatology 34 (2001) 1225-1241
20. Lawrence T.S., Ten Haken R.K., Kessler M.L., et al. The use of 3-D dose volume analysis to predict radiation hepatitis. Int J Radiat Oncol Biol Phys 23 (1992) 781-788
21. Trotti A., Byhardt R., Stetz J., et al. Common toxicity criteria, version 2.0: An improved reference for grading the acute effects of cancer treatment: Impact on radiotherapy. Int J Radiat Oncol Biol Phys 47 (2000) 13-47
22. Park J.W., Park K.W., Cho S.H., et al. Risk of hepatitis B exacerbation is low after transcatheter arterial chemoembolization therapy for patients with HBV-related hepatocellular carcinoma: Report of a prospective study. Am J Gastroenterol 100 (2005) 2194-2200
23. Jang J.W., Choi J.Y., Bae S.H., et al. A randomized controlled study of pre-emptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology 43 (2006) 233-240
24. Perrillo R.P. Acute flares in chronic hepatitis B: The natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 120 (2001) 1009-1022
25. Furuse J., Ishii H., Nagase M., et al. Adverse hepatic events caused by radiotherapy for advanced hepatocellular carcinoma. J Gastroenterol Hepatol 20 (2005) 1512-1518
26. Geschwind J.F., Salem R., Carr B.I., et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 127 (2004) S194-S205
27. Jakobs T.F., Hoffmann R.T., Poepperl G., et al. Mid-term results in otherwise treatment refractory primary or secondary liver confined tumours treated with selective internal radiation therapy (SIRT) using (90)Yttrium resin-microspheres. Eur Radiol 17 (2007) 1320-1330 Epub 2006 Dec 6
28. Sato K., Lewandowski R.J., Bui J.T., et al. Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere): Assessment of hepatic arterial embolization. Cardiovasc Intervent Radiol 29 (2006) 522-529
29. Ogata K., Hizawa K., Yoshida M., et al. Hepatic injury following irradiation-A morphologic study. Tokushima J Exp Med 43 (1963) 240-251
30. Therasse P., Arbuck S.G., Eisenhauer E.A., et al., for the European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92 (2000) 205-216
31. Zhong S., Yeo W., Schroder C., et al. High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy. J Viral Hepat 11 (2004) 55-59
32. Hui C.K., Cheung W.W., Au W.Y., et al. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut 54 (2005) 1597-1603
33. Yeo W., and Johnson P.J. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 43 (2006) 209-220